➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
McKinsey
Harvard Business School
Merck
Medtronic

Last Updated: September 26, 2021

DrugPatentWatch Database Preview

Investigational Drug Information for AT-527


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug AT-527?

AT-527 is an investigational drug.

There have been 12 clinical trials for AT-527. The most recent clinical trial was a Phase 1 trial, which was initiated on April 28th 2021.

The most common disease conditions in clinical trials are Hepatitis C, Chronic, Hepatitis C, and Hepatitis A. The leading clinical trial sponsors are Atea Pharmaceuticals, Inc., Hoffmann-La Roche, and [disabled in preview].

There are six US patents protecting this investigational drug and forty-four international patents.

Recent Clinical Trials for AT-527
TitleSponsorPhase
Mass Balance Study of AT-527 in Healthy Adult Male Subjects (R07496998)Hoffmann-La RochePhase 1
Mass Balance Study of AT-527 in Healthy Adult Male Subjects (R07496998)Atea Pharmaceuticals, Inc.Phase 1
Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19Hoffmann-La RochePhase 3

See all AT-527 clinical trials

Clinical Trial Summary for AT-527

Top disease conditions for AT-527
Top clinical trial sponsors for AT-527

See all AT-527 clinical trials

US Patents for AT-527

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AT-527 ⤷  Free Forever Trial .beta.-D-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-C-substituted-2-modified-N.s- up.6-substituted purine nucleotides for HCV treatment Atea Pharmaceuticals, Inc. (Boston, MA) ⤷  Free Forever Trial
AT-527 ⤷  Free Forever Trial .beta.-D-2'-deoxy-2'-.alpha.-fluoro-2'.beta.-C-substituted-2-modified-N.su- p.6-substituted purine nucleotides for HCV treatment Atea Pharmaceuticals, Inc. (Boston, MA) ⤷  Free Forever Trial
AT-527 ⤷  Free Forever Trial Beta-D-2'-deoxy-2'-alpha-fluoro-2'-beta-C-substituted-2-modified-N6-substi- tuted purine nucleotides for HCV treatment Atea Pharmaceuticals, Inc. (Boston, MA) ⤷  Free Forever Trial
AT-527 ⤷  Free Forever Trial Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus Atea Pharmaceuticals, Inc. (Boston, MA) ⤷  Free Forever Trial
AT-527 ⤷  Free Forever Trial .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n.s- up.6-substituted purine nucleotides for HCV treatment Atea Pharmaceuticals, Inc. (Boston, MA) ⤷  Free Forever Trial
AT-527 ⤷  Free Forever Trial .beta.-D-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-C-substituted-2-modified-N.s- up.6-substituted purine nucleotides for HCV treatment Atea Pharmaceuticals, Inc. (Boston, MA) ⤷  Free Forever Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AT-527

Drugname Country Document Number Estimated Expiration Related US Patent
AT-527 Australia AU2016229966 2035-03-06 ⤷  Free Forever Trial
AT-527 Australia AU2018282469 2035-03-06 ⤷  Free Forever Trial
AT-527 Australia AU2020203055 2035-03-06 ⤷  Free Forever Trial
AT-527 Australia AU2021204022 2035-03-06 ⤷  Free Forever Trial
AT-527 Brazil BR112017018977 2035-03-06 ⤷  Free Forever Trial
AT-527 Canada CA2978085 2035-03-06 ⤷  Free Forever Trial
AT-527 China CN107427530 2035-03-06 ⤷  Free Forever Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
Medtronic
Mallinckrodt
AstraZeneca
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.